Relevance of mouse models of cardiac fibrosis and hypertrophy in cardiac research

被引:0
|
作者
Vikrant Rai
Poonam Sharma
Swati Agrawal
Devendra K. Agrawal
机构
[1] Creighton University School of Medicine,Department of Clinical & Translational Science, The Peekie Nash Carpenter Endowed Chair in Medicine
[2] Creighton University School of Medicine,Department of Pathology
来源
关键词
Ischemic reperfusion injury; Myocardial infarction; Congestive heart failure; Cardiac remodeling; Cardiac fibrosis and hypertrophy; Mouse models;
D O I
暂无
中图分类号
学科分类号
摘要
Heart disease causing cardiac cell death due to ischemia–reperfusion injury is a major cause of morbidity and mortality in the United States. Coronary heart disease and cardiomyopathies are the major cause for congestive heart failure, and thrombosis of the coronary arteries is the most common cause of myocardial infarction. Cardiac injury is followed by post-injury cardiac remodeling or fibrosis. Cardiac fibrosis is characterized by net accumulation of extracellular matrix proteins in the cardiac interstitium and results in both systolic and diastolic dysfunctions. It has been suggested by both experimental and clinical evidence that fibrotic changes in the heart are reversible. Hence, it is vital to understand the mechanism involved in the initiation, progression, and resolution of cardiac fibrosis to design anti-fibrotic treatment modalities. Animal models are of great importance for cardiovascular research studies. With the developing research field, the choice of selecting an animal model for the proposed research study is crucial for its outcome and translational purpose. Compared to large animal models for cardiac research, the mouse model is preferred by many investigators because of genetic manipulations and easier handling. This critical review is focused to provide insight to young researchers about the various mouse models, advantages and disadvantages, and their use in research pertaining to cardiac fibrosis and hypertrophy.
引用
收藏
页码:123 / 145
页数:22
相关论文
共 50 条
  • [21] Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II - Induced cardiac hypertrophy
    Matsui, Y
    Jia, N
    Okamoto, H
    Kon, S
    Onozuka, H
    Akino, M
    Liu, LZ
    Morimoto, J
    Rittling, SR
    Denhardt, D
    Kitabatake, A
    Uede, T
    HYPERTENSION, 2004, 43 (06) : 1195 - 1201
  • [22] MOLECULAR AND CELLULAR MECHANISMS OF INDUCTION AND REGRESSION OF CARDIAC FIBROSIS IN VARIOUS MODELS OF MYOCARDIAL HYPERTROPHY
    EGHBALI, M
    CARDIOVASCULAR PATHOLOGY, 1993, 2 (03) : 199 - 205
  • [23] Suppressive Effects of Glucose-dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
    Hiromura, Munenori
    Mori, Yusaku
    Kohashi, Kyoko
    Terasaki, Michishige
    Shinmura, Kyoko
    Kushima, Hideki
    Tomoyasu, Masako
    Yamada, Yuichiro
    Watanabe, Takuya
    Hirano, Tsutomu
    DIABETES, 2016, 65 : A57 - A57
  • [24] Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
    Hiromura, Munenori
    Mori, Yusaku
    Kohashi, Kyoko
    Terasaki, Michishige
    Shinmura, Kyoko
    Negoro, Takaharu
    Kawashima, Hikaru
    Kogure, Mao
    Wachi, Toshimi
    Watanabe, Rena
    Sato, Kengo
    Kushima, Hideki
    Tomoyasu, Masako
    Nakano, Yasuko
    Yamada, Yuichiro
    Watanabe, Takuya
    Hirano, Tsutomu
    CIRCULATION JOURNAL, 2016, 80 (09) : 1988 - +
  • [25] FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes
    Christopher Yanucil
    Dominik Kentrup
    Xueyi Li
    Alexander Grabner
    Karla Schramm
    Eliana C. Martinez
    Jinliang Li
    Isaac Campos
    Brian Czaya
    Kylie Heitman
    David Westbrook
    Adam R. Wende
    Alexis Sloan
    Johanna M. Roche
    Alessia Fornoni
    Michael S. Kapiloff
    Christian Faul
    Scientific Reports, 12
  • [26] FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes
    Yanucil, Christopher
    Kentrup, Dominik
    Li, Xueyi
    Grabner, Alexander
    Schramm, Karla
    Martinez, Eliana C.
    Li, Jinliang
    Campos, Isaac
    Czaya, Brian
    Heitman, Kylie
    Westbrook, David
    Wende, Adam R.
    Sloan, Alexis
    Roche, Johanna M.
    Fornoni, Alessia
    Kapiloff, Michael S.
    Faul, Christian
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [27] Bone Morphogenetic Protein-4 Mediates Cardiac Hypertrophy, Apoptosis, and Fibrosis in Experimentally Pathological Cardiac Hypertrophy
    Sun, Bo
    Huo, Rong
    Sheng, Yue
    Li, Yue
    Xie, Xin
    Chen, Chang
    Liu, Hui-Bin
    Li, Na
    Li, Cheng-Bo
    Guo, Wen-Ting
    Zhu, Jiu-Xin
    Yang, Bao-Feng
    Dong, De-Li
    HYPERTENSION, 2013, 61 (02) : 352 - +
  • [28] Erratum to: Disruption of mindin exacerbates cardiac hypertrophy and fibrosis
    Zhou-Yan Bian
    Xiang Wei
    Shan Deng
    Qi-Zhu Tang
    Jinghua Feng
    Yan Zhang
    Chen Liu
    Ding-Sheng Jiang
    Ling Yan
    Lian-Feng Zhang
    Manyin Chen
    John Fassett
    Yingjie Chen
    You-Wen He
    Qinglin Yang
    Peter P. Liu
    Hongliang Li
    Journal of Molecular Medicine, 2017, 95 : 1251 - 1253
  • [29] Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis
    Anderson, M.
    Moore, D.
    Larson, D. F.
    PERFUSION-UK, 2008, 23 (04): : 231 - 235
  • [30] Epigenetic Modifying Therapy for the Treatment of Cardiac Fibrosis and Hypertrophy
    Watson, C.
    Horgan, S.
    Neary, R.
    Collier, P.
    Tea, I
    Glezeva, N.
    Ledwidge, M.
    McDonald, K.
    Baugh, J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S421 - S422